Your browser doesn't support javascript.
loading
Multicenter Prospective Cohort Study of the Diagnostic Yield and Patient Experience of Multiplex Gene Panel Testing For Hereditary Cancer Risk.
Idos, Gregory E; Kurian, Allison W; Ricker, Charité; Sturgeon, Duveen; Culver, Julie O; Kingham, Kerry E; Koff, Rachel; Chun, Nicolette M; Rowe-Teeter, Courtney; Lebensohn, Alexandra P; Levonian, Peter; Lowstuter, Katrina; Partynski, Katlyn; Hong, Christine; Mills, Meredith A; Petrovchich, Iva; Ma, Cindy S; Hartman, Anne-Renee; Allen, Brian; Wenstrup, Richard J; Lancaster, Johnathan M; Brown, Krystal; Kidd, John; Evans, Brent; Mukherjee, Bhramar; McDonnell, Kevin J; Ladabaum, Uri; Ford, James M; Gruber, Stephen B.
Afiliación
  • Idos GE; University of Southern California, Los Angeles, CA.
  • Kurian AW; Stanford University School of Medicine, Stanford, CA.
  • Ricker C; University of Southern California, Los Angeles, CA.
  • Sturgeon D; University of Southern California, Los Angeles, CA.
  • Culver JO; University of Southern California, Los Angeles, CA.
  • Kingham KE; Stanford University School of Medicine, Stanford, CA.
  • Koff R; Stanford University School of Medicine, Stanford, CA.
  • Chun NM; Stanford University School of Medicine, Stanford, CA.
  • Rowe-Teeter C; Stanford University School of Medicine, Stanford, CA.
  • Lebensohn AP; Stanford University School of Medicine, Stanford, CA.
  • Levonian P; Stanford University School of Medicine, Stanford, CA.
  • Lowstuter K; University of Southern California, Los Angeles, CA.
  • Partynski K; University of Southern California, Los Angeles, CA.
  • Hong C; University of Southern California, Los Angeles, CA.
  • Mills MA; Stanford University School of Medicine, Stanford, CA.
  • Petrovchich I; Stanford University School of Medicine, Stanford, CA.
  • Ma CS; Stanford University School of Medicine, Stanford, CA.
  • Hartman AR; Myriad Genetics, Salt Lake City, UT.
  • Allen B; Myriad Genetics, Salt Lake City, UT.
  • Wenstrup RJ; Myriad Genetics, Salt Lake City, UT.
  • Lancaster JM; Myriad Genetics, Salt Lake City, UT.
  • Brown K; Myriad Genetics, Salt Lake City, UT.
  • Kidd J; Myriad Genetics, Salt Lake City, UT.
  • Evans B; Myriad Genetics, Salt Lake City, UT.
  • Mukherjee B; University of Michigan, Ann Arbor, MI.
  • McDonnell KJ; University of Southern California, Los Angeles, CA.
  • Ladabaum U; Stanford University School of Medicine, Stanford, CA.
  • Ford JM; Stanford University School of Medicine, Stanford, CA.
  • Gruber SB; University of Southern California, Los Angeles, CA.
JCO Precis Oncol ; 32019 Mar.
Article en En | MEDLINE | ID: mdl-34322651
PURPOSE: Multiplex gene panel testing (MGPT) allows for the simultaneous analysis of germline cancer susceptibility genes. This study describes the diagnostic yield and patient experiences of MGPT in diverse populations. PATIENTS AND METHODS: This multicenter, prospective cohort study enrolled participants from three cancer genetics clinics-University of Southern California Norris Comprehensive Cancer Center, Los Angeles County and University of Southern California Medical Center, and Stanford Cancer Institute-who met testing guidelines or had a 2.5% or greater probability of a pathogenic variant (N = 2,000). All patients underwent 25- or 28-gene MGPT and results were compared with differential genetic diagnoses generated by pretest expert clinical assessment. Post-test surveys on distress, uncertainty, and positive experiences were administered at 3 months (69% response rate) and 1 year (57% response rate). RESULTS: Of 2,000 participants, 81% were female, 41% were Hispanic, 26% were Spanish speaking only, and 30% completed high school or less education. A total of 242 participants (12%) carried one or more pathogenic variant (positive), 689 (34%) carried one or more variant of uncertain significance (VUS), and 1,069 (53%) carried no pathogenic variants or VUS (negative). More than one third of pathogenic variants (34%) were not included in the differential diagnosis. After testing, few patients (4%) had prophylactic surgery, most (92%) never regretted testing, and most (80%) wanted to know all results, even those of uncertain significance. Positive patients were twice as likely as negative/VUS patients (83% v 41%; P < .001) to encourage their relatives to be tested. CONCLUSION: In a racially/ethnically and socioeconomically diverse cohort, MGPT increased diagnostic yield. More than one third of identified pathogenic variants were not clinically anticipated. Patient regret and prophylactic surgery use were low, and patients appropriately encouraged relatives to be tested for clinically relevant results.

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Qualitative_research / Risk_factors_studies Idioma: En Revista: JCO Precis Oncol Año: 2019 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Guideline / Observational_studies / Qualitative_research / Risk_factors_studies Idioma: En Revista: JCO Precis Oncol Año: 2019 Tipo del documento: Article